PATENT CLAIM ANALYSIS

Application Number: 16132247
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["536", "024500"]

Abstract:
The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.

Claim (Index 31):
The pharmaceutical combination of  claim 27 , wherein the shRNA comprises a sequence having at least 80% identity with SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 97.0
- Lexical Diversity: 1.15625
- Patent Class: 536.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16008991', '15904131', '15652080', '15849062', '15706481']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7944242099864797
- 35 USC 102 Novelty (BERT): 0.6173688640064674
- Combined Prediction Score: 0.7767186753884785
- Mean Citation Score: 661.851448
- Max Citation Score: 713.7021
- Similarity Product: 483.16363492260575

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test